Blood News and Research

RSS

Tracking heart rate can provide important marker of health issues: Research

An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

Study examines comparative value of different blood pressure lowering medications

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study.Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heat Attack Trial (ALLHAT), which has examined the comparative value of different blood pressure-lowering medications.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

The American Society of Hematology has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released today in Blood, ASH's premier scientific journal, in the article titled "Enhancing Research in Regenerative Medicine."

13 Aug 2010

Arrowhead third-quarter 2010 net loss decreases to $0.4 million

Arrowhead Research Corporation today announced financial results for its fiscal 2010 third quarter ended June 30, 2010.

13 Aug 2010

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal a new 510(k) clearance for its Amicus® blood cell separator.

13 Aug 2010

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

LifeCycle Pharma A/S today announced receipt of agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment of its pivotal Phase 3 study, Study 3002, for LCP-Tacro in patients, who have just received a kidney transplant.

12 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

BioMimetic Therapeutics, Inc. today announced that it has received orphan drug designation from the Food and Drug Administration for its protein therapeutic, recombinant human platelet derived growth factor, to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans of the knee, elbow or ankle.

12 Aug 2010

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

In type 1 diabetes, the body relentlessly attacks and destroys its own insulin-producing pancreatic beta cells. But a study by Joslin Diabetes Center scientists now has firmly established that some of these cells endure for many decades in a small group of people with the disease—offering clues to potential treatments for preserving and even restoring the crucial cell population.

12 Aug 2010

NYBC calls for blood donations

New York Blood Center, serving more than 20 million people in New York City, Long Island, the Hudson Valley, New Jersey, and parts of Connecticut and Pennsylvania, calls upon the communities it serves to remember your neighbors during this slow, late summer period for blood donations – and schedule a donation appointment or consider sponsoring a blood drive, because patients' needs do not take a summer break.

12 Aug 2010

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

Researchers have been able to use a common chaperone protein, Hsp70, to reverse the loss of function in the nerves of mice with diabetes.Writing in ASN NEURO, Michael J. Urban and colleagues at the University of Kansas suggest that Hsp70 could be used in the future to cure the loss of feeling in the limbs that afflicts many diabetics.

12 Aug 2010

25% of stroke patients stop taking prevention medication within 3 months

At least a quarter of patients who have suffered a stroke stop taking one or more of their prescribed stroke prevention medications within the first three months after being hospitalized - when the chance of having another stroke is highest - according to a new study by researchers at Wake Forest University Baptist Medical Center and colleagues.

12 Aug 2010

Early administration of TXA reduces death from bleeding without increase in complications: Study

If recently injured patients with serious bleeding were to receive a cheap, widely available and easily administered drug to help their blood to clot, tens of thousands of lives could be saved every year, according to a paper published on-line today by The Lancet.

12 Aug 2010

Notre Dame, Madison Center collaborate to research on mental health therapies

Daniel Lapsley, Ph.D., Chairman of the Department of Psychology for Notre Dame University, gives a significant amount of credit to Madison Center, Indiana's largest community mental health agency, for Notre Dame's coup in recruiting two world-class researchers. Now Notre Dame and Madison Center have created a partnership to collaborate on research that is designed to improve treatment and therapies for mental health patients.

12 Aug 2010

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

BioGenerator, a non-profit, seed-stage economic development funding group, today announced that it has led a round of early-stage financing for Pulse Therapeutics, Inc., a St. Louis company headquartered at the Center for Emerging Technologies. Pulse Therapeutics develops innovative magnetism-based technology to safely destroy blood clots related to ischemic stroke and deep vein thrombosis (DVT). Other investors who participated in the round were Missouri Technology Corporation (MTC), Washington University's Olin School of Business Skandalaris Student Venture Fund, and Integrated Magnetics, of Culver City, California. The funds will be used for further pre-clinical development.

12 Aug 2010

Hospital staph infection rate drops as national prevention effort steps up

The rate of drug-resistant staph hospital-acquired infections has dropped as the U.S. has stepped up prevention efforts to fight the deadly condition, The Associated Press reports. "The decline was seen in a federal study of methicillin-resistant staph, or MRSA. The bug often causes only a boil or skin infection. But researchers in the study focused on invasive cases that can become deadly, invading the bloodstream, flesh, lungs and bones. Researchers found that in nine metro areas, cases of MRSA (MUR'-suh) fell about 16 percent between 2005 and 2008.

12 Aug 2010

Blood News and Research

Tracking heart rate can provide important marker of health issues: Research

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

Study examines comparative value of different blood pressure lowering medications

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

Arrowhead third-quarter 2010 net loss decreases to $0.4 million

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

FDA grants LifeCycle Pharma SPA for LCP-Tacro pivotal Phase 3 study in 'de novo' kidney transplant patients

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

FDA grants BioMimetic Therapeutics orphan drug designation for rhPDGF-BB in treatment of OCD

Study offers clues to potential treatments for preserving, restoring insulin-producing cells

NYBC calls for blood donations

Researchers suggest Hsp70 can reverse Diabetic peripheral neuropathy

25% of stroke patients stop taking prevention medication within 3 months

Early administration of TXA reduces death from bleeding without increase in complications: Study

Notre Dame, Madison Center collaborate to research on mental health therapies

Pulse Therapeutics receives fund to develop novel magnetics technique to destroy blood clots

Hospital staph infection rate drops as national prevention effort steps up

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News